evaluating treatment centers for stage 2 peritoneal - surgery vs chemo vs multimodal

Yeah, surgeon volume matters big time with meso - I'd push hard on that number and ask for their complication rates too, not just case count. And don't let them dodge the question about whether their oncology and surgery teams actually talk to each other or if you're just getting passed between departments.

I'm gonna be straight with you, your situation is different from mine but the evaluation piece matters everywhere. I had pleural, stage II, so surgery was my path. Had it done in December at UCSD and the surgeon there had done north of 150 meso cases. That number mattered to me because when they're cracking your chest open you want someone who's seen every variation of how this thing grows.

What I found out talking to different places is that some centers really do have their teams locked in together and some are just departments that happen to be in the same building. Ask them straight up if the surgeon, the medical oncologist, and the palliative care doc actually meet together to discuss your case before treatment starts or if you're just getting shuffled between specialists. At UCSD they had me in a room with all three of them same day. That was real multimodal. Other places I called, the surgeon didn't even know who my chemo doc would be yet.

The pathology review thing is legit important. Ask if they do their own path review or if they just take whatever your initial biopsy showed. Some centers will re-examine your samples with their own pathologist because staging can change things and it affects what chemo protocol makes sense. That's a real difference, not just something fancy they say.

On the neoadjuvant versus surgery first question, I can't tell you which is right for peritoneal since I didn't face that choice. But I will say the surgeon at UCSD walked me through why they wanted surgery first for my type and situation and it wasn't just "that's what we do here." They could explain the reasoning. If a center can't explain why their sequence is better for your specific staging, that's a red flag.

You've got good instincts already. Keep pulling those PDFs. When you talk to centers, ask about their five year survival rates for stage II peritoneal specifically, not just general meso numbers. And ask what percentage of their patients actually complete the full multimodal course versus having to bail out partway through due to complications or just can't handle it physically.

The CA-125 tracking is smart. Keep that going.

You're asking exactly the right questions and honestly it's impressive you're this methodical three weeks in. Most people are still in shock at this point.

So here's what we found with my dad. He's Stage IV pleural, not peritoneal, so different beast, but the evaluation process taught me something. Volume absolutely matters. We initially went to a surgeon who had done maybe 30-40 meso cases and his whole pitch was EPP plus aggressive chemo. Then we got to MD Anderson and talked to someone who'd done over 300 cases and his entire approach was different. He actually said EPP might not be appropriate for my dad's staging, which nobody else had mentioned. The difference wasn't just experience, it was that the high-volume surgeon could articulate exactly why each decision was being made instead of just cycling through the standard protocol.

For your evaluation specifically, ask them to walk you through their actual coordination process. Like literally ask "show me how your surgical team talks to your oncology team between phases." One place we looked at, the surgeon and medical oncologist didn't even share the same EMR. That's not multimodal, that's just sequential treatments. At MD Anderson they had tumor board conferences where my dad's case got reviewed across departments before and after each phase. You'll hear the difference immediately in how they answer that question.

About pathology review, ask if they do in-house confirmation or if they're working off your Cleveland Clinic slides. Then ask if they'd re-review if there was any ambiguity. We had a pathology discrepancy that actually mattered for staging and the high-volume centers took that seriously.

Your CA-125 tracking is smart but also ask them what their actual endpoints are. Different centers define response differently. Some use imaging, some use tumor markers, some use both. Know which one matters at each place.

The honest thing though is that at Stage II peritoneal you're in a window where aggressive multimodal actually has real data behind it, unlike some of the later stages where we're basically throwing everything and hoping. That's the one advantage of where you are right now. The trade-off is that means the surgery is serious business and surgeon volume does correlate with complication rates in the literature.

One more thing. Ask each center about their follow-up protocol after treatment ends. How often are you imaging? How often are you seeing oncology? We learned that some places basically discharge you after treatment and others keep you on structured surveillance. That mattered more to us than we expected.

You've got time to get this right. Three weeks in is still early decision-making even though it feels urgent.

Hey, one thing nobody's mentioned yet is asking them point blank about their tumor board. Like, do they actually have surgeons, oncologists, and pathologists sitting in the same room looking at YOUR scans together, or are they just handing off reports between departments. I had my EPP done in February at a place that does this every Tuesday morning and you could tell the difference. My surgeon literally said in my pre-op meeting "the chemo team and I already talked through your case and here's what we're thinking for sequencing" instead of me being the messenger between three silos.

Also ask about their neoadjuvant approach specifically if they're offering it. My place wasn't pushing it for my stage but they had a whole protocol written down for who gets it and why, not just a maybe-or-maybe-not situation. The fact that you got three different answers from three centers is actually pretty normal with meso since the data isn't as locked down as with other cancers, but a good center should be able to explain their reasoning in a way that makes sense given your specific pathology, not just their general preference.

One more thing, ask if they'll do a second pathology review on your biopsy sample. Sounds like admin stuff but it matters, especially early on when you're trying to nail down staging.